medigraphic.com
ISSN 2448-8909 (Impreso)

2007, Número 3

<< Anterior Siguiente >>

Med Crit 2007; 21 (3)


Síndrome de hiperestimulación ovárica

Duarte MJ, Mijangos CJ, Barragán GJA, Díaz MS, Lee Eng CVE

Idioma: Español
Referencias bibliográficas: 37
Paginas: 135-142
Archivo PDF: 116.48 Kb.


RESUMEN

El síndrome de hiperestimulación ovárica (SHEO), es una complicación iatrogénica rara de la estimulación ovárica, llevada a cabo durante la fase lútea o bien durante el embarazo temprano. El síndrome de hiperestimulación ovárica es una complicación potencial de cualquier agente usado para la estimulación ovárica. Hoy, debido a los protocolos más agresivos, incluyendo el desarrollo de fertilización in vitro y la criopreservación, con la meta de obtener un número suficiente de oocitos y embriones, se ha incrementado el riesgo de desarrollar SHEO. Pacientes con las formas severas del SHEO pueden estar críticamente enfermas y requerir de una intervención médica agresiva. No hay tratamiento específico, la terapia es de soporte hasta que la condición se resuelve.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Avecillas JF, Falcone T, Arroliga AC. Ovarian hyperstimulation syndrome. Crit Care Clin 2004;20:679-695.

  2. Marie M. Budev, Ovarian hyperstimulation syndrome. Crit Care Med 2005;33[Suppl.]:S301-S306.

  3. Rydberg E, Pedersen-Bjergaard K. Effect of serum gonadotropin and chorionic gonadotropin on the human ovary. JAMA 1943;121:1117-1122.

  4. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS). Human Reproduction Update 2003;9:77-96.

  5. Whelan III JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73(5):883-96.

  6. Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N Engl J Med 2003;349(8):760-6.

  7. Shanbhag S, Bhattacharya S. Current management of ovarian hyperstimulation syndrome. Hosp Med 2002; 63(9):528-32.

  8. Navot D. Severe ovarian hyperstimulation syndrome. In: Gardner DK, editor. Textbook of assisted reproductive techniques: laboratory and clinical perspectives. 1st edition. London:Martin Dunitz; 2001:645-54.

  9. Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003;349(8):729-32.

  10. Vasseur C, Rodien P, Beau I, Desroches A, Gerard C, de poncheville L et al. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003;349(8):753-9.

  11. Balasch J, Fabregues F, Arroyo V, Jimenez W, Creus M, Vanrell JA. Treatment of severe ovarian hyperstimulation syndrome by a conservative medical approach. Acta Obstet Gynecol Scand 1996;75:662-7.

  12. Brinsden PR, Wada I, Tan SL, Balen A, Jacobs HS. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995; 102:767-72.

  13. Kaiser UB. The pathogenesis of the ovarian hyperstimulation syndrome. N Engl J Med 2003;349.

  14. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Human Reproduction Update 2002;8:559-77.

  15. Vasseur C, Rodien P, Beau I et al. A chronic gonadotropin-sensitive mutation in the follicles stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N Engl J Med 2003; 349:753-9.

  16. Montanelli L, Delbaere A, Di Carlo C et al. A mutation in the follicle stimulation hormone receptor as a cause of familial spontaneous ovarian stimulation syndrome. J Clin Endocr Metabol 2004;89:1255-1258 9. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil and Steril 2004; 82:S81–S86

  17. Navot D, Bergh PA, Laufer N. The ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992; 58:249-61.

  18. Garcia-Velasco JA, Pellicer A. New concepts in the understanding of the ovarian hyperstimulation syndrome. Curr Opin Obstet Gynecol 2003;15:251-6.

  19. Kol S. Lutolysis induced by a gonadotropin releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004;81:1-5.

  20. van Wely M, Westergaard LG, Bossuyt PM et al. Effectiveness of human menopausal gonadotropin versus recombinant follicle stimulation hormone for controlled ovarian hyperstimulation in assisted reproductive cycles. A meta-analysis. Fertil Steril 2003;80:1086-1093.

  21. Enskog A, Henriksson M, Unander M, Nilsson L, Brannstron M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71(5):808-14.

  22. Felberbaum RE, Diedrich K. Gonadotrophin releasing hormone antagonists: Will they replace the agonists? Reprod Biomed Online 2003;6:43-53.

  23. Aboulghar M, Evers JH, Al-Inany H. Intravenous albumin for the preventing severe ovarian hyperstimulation syndrome: A Cochran review. Hum Reprod 2002;17:3027-32.

  24. Turkistani IM, Ghourab SA, Al-Sheikh OH et al. Central retinal artery occlusion associated with severe ovarian hyperstimulation syndrome. Eur J Ophthalmol 2001;11:313-5.

  25. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth EJ. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1988;159:210-5.

  26. Fawzy M, Harrison RF, Walshe J. Ovarian hyperstimulation syndrome: Diagnosis, prevention, and management. Ir Med J 1998;91:86-87.

  27. Zosmer A, Katz Z, Lancet M et al. Adult respiratory distress syndrome complicating ovarian hyperstimulation syndrome. Fertil Steril 1987;47:524-6.

  28. Borenstein R, Elhalah U, Lunenfeld B et al. Severe ovarian hyperstimulation syndrome: A reevaluated approach. Fertil Steril 1989;51:791-795.

  29. Brower RG, Matthay MA, Morris A et al. The acute respiratory distress syndrome network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.

  30. Serour GI, Aboulghar M, Mansour R et al. Complications of medically assisted conception in 3,500 cycles. Fertil Steril 1998;70:638-42.

  31. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.

  32. Shigematsu T, Kubota E, Arman M. Adult respiratory distress syndrome as a manifestation of ovarian hyperstimulation syndrome. Int J Gynaecol Obstet 2000;69:169-170.

  33. Abuzeid MI, Nassar Z, Massaad Z et al. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 2003;18:370-3.

  34. Fukaya T, Chida S, Terada Y et al. Treatment of severe ovarian hyperstimulation syndrome by ultrafiltration and re-infusion of ascetic fluid. Fertil Steril 1994;77:1302-3.

  35. Pride SM, Yuen BH, Moon YS. Clinical, endocrinologic, and intraovarian prostacyclin F responses to H-1 receptor blockade in the ovarian hyperstimulation syndrome: Studies in the rabbit model. Am J Obstet Gynecol 1986;154:1155-60.

  36. Gergely RZ, Paldi E, Erlik Y et al. Treatment of ovarian hyperstimulation syndrome by antihistamine. Obstet Gynecol 1976;47:83-5.

  37. Chew S, Ng SC. Laparoscopic treatment of a twisted hyperstimulated ovary after IVF. Singapore Med J 2001; 42:228-9.




2020     |     www.medigraphic.com